<![CDATA[Current Nanomedicine (Volume 14 - Issue 2)]]> https://www.benthamscience.com/journal/161 RSS Feed for Journals | BenthamScience EurekaSelect (+https://www.benthamscience.com) 2024-03-07 <![CDATA[Current Nanomedicine (Volume 14 - Issue 2)]]> https://www.benthamscience.com/journal/161 <![CDATA[<i>Trans</i>-resveratrol-glycyrrhetinic Acid Loaded in Nanocarrier-based Regimen to Overcome the Complications of Existing Therapies in Skin Melanoma]]>https://www.benthamscience.com/article/1350212024-03-07 <![CDATA[Nanosuspension as a Novel Nanovehicle for Drug Delivery: A Recent Update on Patents and Therapeutic Applications]]>https://www.benthamscience.com/article/1357922024-03-07 <![CDATA[Nanotechnological Carriers in the Treatment of Cancer: A Review]]>https://www.benthamscience.com/article/1351482024-03-07 <![CDATA[Cancer-Specific Nanomedicine Delivery Systems and the Role of the Tumor Microenvironment: A Critical Linkage]]>https://www.benthamscience.com/article/1357942024-03-07Background: The tumour microenvironment (TME) affects tumour development in a crucial way. Infinite stromal cells and extracellular matrices located in the tumour form complex tissues. The mature TME of epithelial-derived tumours exhibits common features irrespective of the tumour's anatomical locale. TME cells are subjected to hypoxia, oxidative stress, and acidosis, eliciting an extrinsic extracellular matrix (ECM) adjustment initiating responses by neighbouring stromal and immune cells (triggering angiogenesis and metastasis).

Objective: This report delivers challenges associated with targeting the TME for therapeutic pur-poses, technological advancement attempts to enhance understanding of the TME, and debate on strategies for intervening in the pro-tumour microenvironment to boost curative benefits.

Conclusion: Therapeutic targeting of TME has begun as an encouraging approach for cancer treatment owing to its imperative role in regulating tumour progression and modulating treatment response.

]]>
<![CDATA[A Review on Nanostructured Lipid Carriers as Promising Drug Delivery Vehicle to Target Various Cancers via Oral Route: A Step towards “Chemotherapy at Home”]]>https://www.benthamscience.com/article/1361382024-03-07 <![CDATA[Formulation, Optimization and Evaluation of Dabigartan Etexilate Encapsulated Solid Supersaturated Self-Nanoemulsifying Drug Delivery System]]>https://www.benthamscience.com/article/1375262024-03-07 Objective: The present study proposed Dabigatran Etexilate loaded solid supersaturated self-nanoemulsifying drug delivery system (solid S-SNEDDS) for enhancement of payload, drug solubility, dissolution rate as well as minimization of drug precipitation.

Methods: The study involved formulation optimization using the Box-Behnken design. The optimal SNEDDS consisting of Caprylic acid (32.9% w/w), Cremophor EL (50.2% w/w) and Transcutol HP (18.8% w/w) as Oil, Surfactant and Co-surfactant, respectively were formulated and evaluated for particle size, PDI, Zeta potential and saturation solubility. The SNEDDS was further incorporated with PPIs for the preparation of supersaturated SNEDDS (S-SNEDDS) to increase the drug payload in the formulation. S-SNEDDS was converted to solid S-SNEDDS by ad-sorption onto the porous carrier i.e., Aerosil®200. The in-vitro drug release study was also conducted for solid S-SNEDDS.

Results: SNEDDS had size, PDI, and Zeta potential of 82nm, 0.347, -10.50mV, respectively. SNEDDS enhanced the saturation solubility of the drug by 93.65-fold. Among PPIs, HPMC K4M showed the most effective response for the formulation of S-SNEDDS. The S-SNEDDS had a more substantial drug payload, which further increased the solubility by 150 times of pure drugs and 16 times of SNEDDS. Solid S-SNEDDS exhibited free-flowing properties. Reconstituted sol-id S-SNEDDS had acceptable size, PDI, and Zeta potential of 131.3nm, 0.457, and -11.3 mV, respectively. In-vitro drug release study revealed higher drug dissolution and minimized drug precipitation by SNEDDS compared to marketed products and pure drugs.

Conclusion: Proposed nano-formulation was found to efficiently improve the aqueous solubility of the drug and avoid the drug precipitation, thereby avoiding drug loss and improving drug bioavailability.

]]>
<![CDATA[Development and Characterization of Lipid Nanoparticles Loaded with Antipsychotic Drugs Using Central Composite Design]]>https://www.benthamscience.com/article/1359892024-03-07Background: Fluoxetine and olanzapine combination tablets are available in the market for oral administration in the treatment of depression, but fluoxetine has been shown to have a dose-related side effect due to its high oral dose and ability to undergo excessive first-pass metabolism. Olanzapine has low solubility and low bioavailability.

Objective: The objective of this study was to prepare lipid nanoparticles containing fluoxetine and olanzapine to enhance the solubility and dissolution profile of the drugs.

Methods: Lipid nanoparticles (LNs) were prepared by high-speed homogenization using the ultrasonication method. Different lipids and surfactants were used to screen out the best lipids, surfactants, and their ratio in the preparation of lipid nanoparticles. Drug and polymer compatibility was examined using FTIR and DSC studies. The formulation was optimized using the central composite design to establish functional relationship between independent variables and responses. Optimized batch was characterized using particle size, PDI, zeta potential, % EE, % CDR, and stability.

Results: Phase solubility study revealed FLX to have highest solubility in stearic acid and oleic acid, whereas OLZ showed highest solubility in Precirol ATO 5 and oleic acid. Poloxamer 188 was selected on the basis of high entrapment efficiency of the drug. In LNs, no significant interaction between drug and polymer was confirmed by DSC and FTIR. The particle size of optimized batch was found to be 411.5 nm with 0.532 PDI and - 9.24 mV zeta potential. For FLX and OLZ, the %EE and %CDR after 8h were found to be more than 90%. No significant change in %EE and %CDR of the formulation was observed after 4 weeks of storage.

Conclusion: Experimental results demonstrated excellent drug entrapment as well as controlled release behavior from optimized LNs of FLX and OLZ at reduced dosage frequency.

]]>